You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,731,151

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,731,151

Title:	Regulator of contact-mediated hemolysin
Abstract:	The present invention relates to a nucleic acid that encodes a hemolysin protein and to a nucleic acid that encodes a positive regulator of hemolysis. The nucleic acid can be the basis of a vaccine against tuberculosis. The nucleic acid can be inserted into an avirulent vaccine strain such as M. bovis BCG.
Inventor(s):	King; C. Harold (Rex, GA), Shinnick; Thomas M. (Atlanta, GA), Sathish; Mundayoor (Bombay, IN)
Assignee:	The United States of America as represented by the Secretary of the (Washington, DC)
Application Number:	08/557,115
Patent Claims:	1. The isolated double-stranded nucleic acid set forth in SEQ ID NO:2. 2. The nucleic acid of claim 1 in a vector. 3. An isolated nucleic acid comprising nucleotides 99-1020 of the nucleic acid of claim 1. 4. An isolated nucleic acid comprising SEQ ID NO:2. 5. The nucleic acid of claim 4 operably linked to a reporter gene. 6. The nucleic acid of claim 5 in a vector. 7. The vector of claim 6 in a host suitable for expression of the nucleic acid. 8. An isolated nucleic acid encoding a purified protein comprising the polypeptide set forth in SEQ ID NO:3. 9. A vector comprising the nucleic acid of claim 8. 10. The vector of claim 9 in a host suitable for expression of the nucleic acid. 11. The vector of claim 10, wherein the host is M. bovis BCG. 12. The vector of claim 10, wherein the host is Mycobacterium smegmatis. 13. A method of promoting an immune response in a subject against Mycobacterium tuberculosis comprising administering to the subject the host of claim 11. 14. A method of promoting an immune response in a subject against Mycobacterium tuberculosis comprising administering to the subject the host of claim 12. 15. A method of enhancing the immunogenicity of an M. bovis BCG vaccine in a subject: comprising inserting the vector of claim 9 into the M. bovis BCG vaccine prior to administering the vaccine to the subject.

Details for Patent 5,731,151

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	N/A	bcg vaccine	For Injection	103050	06/21/1989	⤷ Try a Trial	2040-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.